Business Context and Reporting Period
This Form 8-K filing by Rocket Pharmaceuticals, Inc. covers events occurring on January 24, 2018. The company is a Delaware corporation focused on pharmaceutical development. The report details a material definitive agreement regarding a public equity offering and significant changes in executive leadership.
Key Financial Metrics and Capital Events
- Equity Offering: The Company entered into an underwriting agreement to sell 6,325,000 shares of common stock, including the full exercise of an option for 825,000 optional shares.
- Offering Price: Shares were sold to underwriters at $12.455 per share with a public offering price of $13.25 per share.
- Net Proceeds: Estimated net proceeds are approximately $78.5 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: Cowen and Company, LLC and Evercore Group L.L.C. served as representatives.
- Closing Date: Expected on or about January 26, 2018.
The filing does not provide specific data on revenue, operating profit, cash flow, margins, or existing debt levels, as this is a current report focused on specific events rather than a periodic financial statement.
Material Changes and Personnel Updates
- Departure of CFO: Brian Batchelder, Vice President of Finance and the Company's principal financial and accounting officer, passed away on January 24, 2018.
- Appointment of New CFO: On January 25, 2018, the Board appointed John Militello, the Company's Controller, as the new principal financial officer and principal accounting officer.
- Compensation for New Officer: Mr. Militello will receive an annual salary of $190,000, a target bonus of 20% of base salary, and an option to purchase 10,000 shares vesting over three years.
- Lock-Up Agreement: Executive officers, directors, and certain shareholders agreed to a 90-day lock-up period regarding the sale of common stock.
Outlook, Risks, and Contingencies
The Company estimates the offering will close subject to customary closing conditions. The filing notes that the Company agreed to indemnify underwriters against certain liabilities under the Securities Act. No specific forward-looking guidance regarding product development timelines or future revenue projections is included in this specific filing.
Key Facts for Investor Verification
- Verify the actual closing of the offering and the final net proceeds received on or after January 26, 2018.
- Confirm the impact of the $78.5 million capital raise on the Company's cash runway and liquidity position.
- Monitor the transition of financial reporting responsibilities under the new principal financial officer, John Militello.
- Review the 90-day lock-up expiration date to assess potential future selling pressure from insiders.